Trials / Available
AvailableNCT05170724
Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria
Managed Access Program (MAP) Cohort Treatment Plan CLOU064A2002M to Provide Access to Remibrutinib for Adult Patients With Chronic Spontaneous Urticaria (CSU)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide access to remibrutinib for adult patients with chronic spontaneous urticaria (CSU)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remibrutinib | Remibrutinib should be taken in accordance with the recommendations in the treatment plan. |
Timeline
- First posted
- 2021-12-28
- Last updated
- 2025-12-05
Source: ClinicalTrials.gov record NCT05170724. Inclusion in this directory is not an endorsement.